Decision: Favourable

Decisions Table

Study Title:

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

  • NREC Code:

    21-NREC-CT-021

  • Decision:

    Favourable

  • Meeting Date:

    21/07/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Prof Douglas Veale

  • PI Institution:

    St Vincent's University Hospital

  • Sponsor:

    Bristol Myers Squibb International Corporation

Scroll to Top